Want to join the conversation?
$AGN and $ADMS said the U.S. Food and Drug Administration (FDA) has approved a new, expanded label for NAMZARIC (memantine and donepezil hydrochlorides) extended-release, a combination of memantine hydrochloride and donepezil hydrochloride for the treatment of moderate to severe Alzheimer's disease.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.